Athersys (ATHX) Stock Price
Athersys Price
Revenue at Athersys has contracted by 17.6% per year over the past 19 years to 80,000.00 USD. For Athersys, the net margin of -46,883.8% is down versus -808.1% a few years ago. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Athersys stock price
Athersys business model & stock analysis
Frequently asked questions about Athersys
The business model of Athersys Inc is focused on the development and commercialization of novel regenerative medicine therapies. As a biotechnology company, Athersys is dedicated to leveraging its proprietary MultiStem® cell therapy platform to treat a range of medical conditions. The company collaborates with strategic partners in both commercial and clinical settings to advance its therapies and expand their potential applications. Athersys aims to address significant unmet medical needs and deliver effective, safe, and cost-efficient treatments for conditions such as stroke, acute respiratory distress syndrome (ARDS), and others. Through innovative research and partnerships, Athersys Inc strives to make a positive impact on patients' lives worldwide.
Athersys Inc is primarily active in the biotechnology industry.
The main competitors of Athersys Inc in the market include companies like Mesoblast Limited, Pluristem Therapeutics Inc, and ReNeuron Group plc. These competitors operate in the field of cell therapy and regenerative medicine, similar to Athersys Inc. Each of these companies aims to provide innovative solutions for treating various medical conditions through the use of stem cells and other advanced technologies.
Athersys Inc has a notable history and background in the biotechnology industry. The company, based in Cleveland, Ohio, was founded in 1995 by Dr. Gil Van Bokkelen. Athersys is focused on developing innovative regenerative therapies utilizing its proprietary stem cell technology platform called MultiStem®. Their research and development efforts have paved the way for potential treatments in various areas, including neurological disorders, inflammatory diseases, and cardiovascular conditions. Athersys has collaborated with leading pharmaceutical companies and academic institutions to advance their therapeutic programs. The company's commitment to pioneering regenerative medicine has positioned Athersys as a key player in the healthcare sector.
Athersys Inc, a leading biotechnology company, has achieved several significant milestones. Notably, they successfully completed Phase 2 clinical trials for their MultiStem® cell therapy in patients with ischemic stroke, demonstrating promising results in terms of safety and efficacy. Moreover, Athersys Inc received Fast Track designation from the FDA for the treatment of acute respiratory distress syndrome (ARDS), reflecting the potential impact of their therapy. Their collaborations with renowned institutions and organizations signify strong partnerships and commitment to advancing regenerative medicine. With continuous innovation and dedication, Athersys Inc is poised to make further strides in developing groundbreaking therapies for various unmet medical needs.
Athersys Inc is primarily present in the United States, focusing on developing their innovative regenerative medicine technologies.
Athersys Inc is committed to delivering innovative therapies that improve patients' lives. The company's corporate philosophy revolves around pioneering stem cell research and developing cutting-edge regenerative medicine technologies. Athersys Inc places immense value on scientific excellence and has a strong focus on collaboration and partnerships to drive advancements in healthcare. By leveraging its proprietary MultiStem® cell therapy platform, Athersys Inc aims to address critical medical needs and provide novel treatment options for conditions such as stroke, acute respiratory distress syndrome (ARDS), and other inflammatory and immune conditions. Through its dedication to scientific expertise and patient-centered approach, Athersys Inc strives to contribute to the betterment of healthcare worldwide.
7 analysts currently rate the Athersys stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Athersys to generate revenue of 2.77 B USD and earnings per share of -1.56 USD.
The Athersys share (ATHX) is listed on 5 stock exchanges, including: NASDAQ (ATHX), SIX (Zürich) (4LS.SW), Frankfurt (4LS.F), München (4LS.MU), Düsseldorf (4LS.DU).
Athersys Inc is a biotechnology company focused on developing and commercializing novel therapies for the treatment of diseases. The company is headquartered in Cleveland, Ohio and has subsidiaries in Europe and Asia. Athersys' business model includes three main divisions: regenerative medicine, clinical development, and commercialization. The company has developed a unique technology platform called MultiStem®, which is based on mesenchymal stem cells and has the ability to regulate inflammatory and regenerative processes in the body. The MultiStem technology is currently being studied in clinical trials for the treatment of various indications such as stroke, acute lung injuries, sepsis, and cancer. In the regenerative medicine division, Athersys collaborates closely with research institutions and industry partners to develop new applications for the MultiStem technology. The company has extensive experience in the manufacturing and characterization of mesenchymal stem cells and aims to develop the next generation of cell therapies. Athersys' clinical development division focuses on conducting clinical trials to evaluate the efficacy and safety of MultiStem in various diseases. The company works closely with regulatory authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to obtain approval for MultiStem for the treatment of specific diseases. Finally, Athersys' commercialization division aims to establish MultiStem as an approved drug in the market. Through strategic partnerships with pharmaceutical manufacturers and other companies, the company aims to market MultiStem in different geographic regions and indications. Athersys currently does not have its own product on the market. However, the company collaborates with several pharmaceutical manufacturers and partners to advance the commercialization of MultiStem. Some of Athersys' partners include Pfizer, Healios, Nikon, Chugai, and Helios. In summary, Athersys' business model focuses on using the MultiStem technology for the development of cell-based therapies in regenerative medicine. The company is focused on conducting clinical trials to evaluate the efficacy and safety of MultiStem in the treatment of various diseases. Ultimately, Athersys aims to commercialize MultiStem through partnerships with a wide range of companies and the expansion into different geographic regions.
The expected revenue of Athersys is 2.77 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Athersys is -38.12 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Athersys at the moment.
The P/S cannot be calculated for Athersys currently.
The Eulerpool Quality Score for Athersys is 2/10.
The ISIN of Athersys is US04744L1061. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Athersys is A0M085. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Athersys is ATHX. The ticker symbol is used to trade Athersys shares on the stock exchange.
Athersys stock
Athersys Peer Group
Athersys Ticker
Athersys FIGI
All fundamentals and in-depth analysis of Athersys
Our stock analysis for Athersys stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athersys. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.